Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Intelliject Aims To Build Combination Product Biz On Ease-Of-Use Benefits

This article was originally published in The Gray Sheet

Executive Summary

Human factors engineering has gained traction in the device industry in recent years, but Richmond-based Intelliject is a rare example of a firm trying to build a business around a focus on product usability

You may also be interested in...



New Biosimilar Approval Pathway Creates Device Opportunities

A new abbreviated regulatory pathway established by Congress for the approval of off-patent recombinant protein therapeutics could open up U.S. market opportunities for injection device technology firms

New Biosimilar Approval Pathway Creates Device Opportunities

A new abbreviated regulatory pathway established by Congress for the approval of off-patent recombinant protein therapeutics could open up U.S. market opportunities for injection device technology firms

New Biosimilar Approval Pathway Creates Device Opportunities

Several companies focusing on specialized injectors designed to improve patient comfort and compliance say their technologies will be crucial to differentiating biopharmaceutical products that are vying for the same patient population, but contain virtually the same active ingredient.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026595

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel